Citation Report
List of articles citing

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology

DOI: 10.1007/s40264-018-0778-4
Drug Safety, 2019, 42, 247-262.

#	Paper	IF	Citations
57	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. *Nature Reviews Cancer*, **2019**, 19, 420-438	31.3	52
56	Development of Multi-Target Chemometric Models for the Inhibition of Class I PI3K Enzyme Isoforms: A Case Study Using QSAR-Co Tool. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	12
55	Highlights in Resistance Mechanism Pathways for Combination Therapy. *Cells*, **2019**, 8,	7.9	27
54	Function, Regulation and Biological Roles of PI3K Variants. *Biomolecules*, **2019**, 9,	5.9	15
53	Safety of Novel Targeted Therapies in Oncology. *Drug Safety*, **2019**, 42, 157-158	5.1	1
52	Inhibition of PI3Kinase- s pro-arrhythmic and associated with enhanced late Na current, contractility, and Ca release in murine hearts. *Journal of Molecular and Cellular Cardiology*, **2019**, 132, 98-109	5.8	10
51	Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. *Seminars in Cancer Biology*, **2019**,	12.7	75
50	PI3K n cardioprotection: Cytoskeleton, late Na current, and mechanism of arrhythmias. *Channels*, **2019**, 13, 520-532	3	7
49	Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway. *Toxicology and Applied Pharmacology*, **2020**, 387, 114848	4.6	10
48	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. *Current Heart Failure Reports*, **2020**, 17, 365-383	2.8	13
47	Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1915-1926	4	0
46	Optimization of Versatile Oxindoles as Selective PI3K Inhibitors. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2461-2469	4.3	6
45	Advances in Targeted Therapies for Pediatric Brain Tumors. *Current Treatment Options in Neurology* , **2020**, 22, 1	4.4	5
44	Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors. *Molecular Cancer Therapeutics*, **2020**, 19, 1613-1622	6.1	0
43	Discovery of 3-Quinazolin-4(3)-on-3-yl-2,-dimethylpropanamides as Orally Active and Selective PI3K Inhibitors. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1463-1469	4.3	2
42	Immunological characterization of HM5023507, an orally active PI3K/ Inhibitor. *Pharmacology Research and Perspectives*, **2020**, 8, e00559	3.1	2
41	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 233-248	4.4	6

40	Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes. *Diabetes Research and Clinical Practice*, **2021**, 172, 108633	7.4	5
39	Etiology and management of hypertension in patients with cancer. *Cardio-Oncology*, **2021**, 7, 14	2.8	9
38	Umbralisib, a Dual PI3K⍺/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. *Journal of Clinical Oncology*, **2021**, 39, 1609-1618	2.2	36
37	Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges. *World Journal of Gastrointestinal Oncology*, **2021**, 13, 366-390	3.4	3
36	Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. *Metabolites*, **2021**, 11,	5.6	0
35	A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy. *Medical Science Monitor*, **2021**, 27, e932772	3.2	0
34	Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. *Molecules*, **2021**, 26,	4.8	17
33	SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report. *Clinical Diabetes and Endocrinology*, **2021**, 7, 17	4.7	3
32	Structural Aspects of mTOR Inhibitors: In Progress to Search Potential Compounds. *Anti-Cancer Agents in Medicinal Chemistry*, **2021**,	2.2	0
31	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ. *Frontiers in Immunology*, **2021**, 12, 718621	8.4	3
30	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. *Journal of Hematology and Oncology*, **2021**, 14, 127	22.4	5
29	Establishment of a Lung Cancer Discriminative Model Based on an Optimized Support Vector Machine Algorithm and Study of Key Targets of Wogonin in Lung Cancer. *Frontiers in Pharmacology*, **2021**, 12, 728937	5.6	2
28	Phosphoinositide 3-Kinase δ Inhibition Improves Neutrophil Bacterial Killing in Critically Ill Patients at High Risk of Infection. *Journal of Immunology*, **2021**, 207, 1776-1784	5.3	1
27	Integrated safety analysis of umbralisib, a dual PI3K⍺/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. *Blood Advances*, **2021**, 5, 5332-5343	7.8	2
26	Aloe vera mitigates dextran sulfate sodium-induced rat ulcerative colitis by potentiating colon mucus barrier. *Journal of Ethnopharmacology*, **2021**, 279, 114108	5	4
25	Inhibition of USP1 induces apoptosis via ID1/AKT pathway in B-cell acute lymphoblastic leukemia cells. *International Journal of Medical Sciences*, **2021**, 18, 245-255	3.7	7
24	Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kδ Inhibitors. *ChemMedChem*, **2020**, 15, 539-551	3.7	17
23	Cardiovascular toxicity of PI3Kδ inhibitors. *Clinical Science*, **2020**, 134, 2595-2622	6.5	4

22	Isoform-Selective PI3K Inhibitors for Various Diseases. *Current Topics in Medicinal Chemistry*, **2020**, 20, 1074-1092	3	9
21	Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. *Pharmaceutics*, **2021**, 13,	6.4	0
20	A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. *Cancer Research*, **2021**,	10.1	7
19	PI3K□Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. *Cancers*, **2021**, 13,	6.6	3
18	Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor.. *JAAD Case Reports*, **2022**, 19, 25-27	1.4	1
17	Quantitative systems pharmacology model-based investigation of Adverse Gastrointestinal Events Associated with Prolonged Treatment with PI3-Kinase (PI3K) Inhibitors. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**,	4.5	0
16	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. *Breast Cancer Research and Treatment*, **2021**, 1	4.4	6
15	A multidisciplinary approach to optimizing care of patients treated with alpelisib.. *Breast*, **2021**, 61, 156-167	3.7	1
14	Mechanism of endometrial MUC2 in reproductive performance in mice through PI3K/AKT signaling pathway after lipopolysaccharide treatment.. *Ecotoxicology and Environmental Safety*, **2022**, 231, 113177	7	1
13	Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.. *Current Topics in Medicinal Chemistry*, **2022**,	3	1
12	Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer.. *Frontiers in Oncology*, **2022**, 12, 781233	5.3	2
11	Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer. *Genes and Diseases*, **2022**,	6.6	
10	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas.. *Cancers*, **2022**, 14,	6.6	0
9	The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway.. *Journal of Oncology*, **2022**, 2022, 5871188	4.5	0
8	[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2021 version)]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2021**, 42, 717-727	0.4	0
7	DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.. *Biochemical Pharmacology*, **2022**, 115093	6	0
6	Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.		0
5	Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of the Rapamycin Pathway-Related Protein Expression in Lung Squamous Cell Carcinoma and Its Correlation with Lymph Node Metastasis. **2022**, 2022, 1-7		

4	Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer.	0
3	Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. **2022**, 65, 16033-16061	2
2	Development and safety of PI3K inhibitors in cancer. **2023**, 97, 635-650	0
1	Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies. **2023**, 15, 2279	0